Zoetis Inc. (NYSE:ZTS) Receives $107.43 Average PT from Brokerages

Shares of Zoetis Inc. (NYSE:ZTS) have received an average recommendation of “Hold” from the nineteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $101.0769.

ZTS has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Stifel Nicolaus decreased their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. Piper Sandler lowered their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Finally, UBS Group dropped their price objective on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th.

Zoetis Trading Down 0.4%

NYSE:ZTS opened at $73.00 on Friday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis has a one year low of $71.00 and a one year high of $152.00. The company has a market cap of $30.16 billion, a PE ratio of 12.03, a PEG ratio of 1.71 and a beta of 0.73. The firm has a 50-day moving average of $75.60 and a 200-day moving average of $92.10.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts expect that Zoetis will post 6.2 EPS for the current fiscal year.

Institutional Trading of Zoetis

Institutional investors and hedge funds have recently made changes to their positions in the company. University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis in the 2nd quarter worth about $25,000. Dunhill Financial LLC lifted its position in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Prosperity Bancshares Inc bought a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis in the 1st quarter worth approximately $28,000. Finally, Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.